Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis (DUPLEX)

In the largest FSGS trial to date, the dual endothelin-angiotensin blocker sparsentan lowered urine protein more than the standard blood-pressure drug irbesartan, but over two years it did not meaningfully slow the decline in kidney function compared with irbesartan.